Integra LifeSciences recalls all products manufactured at its Boston, MA facility due to inadequate endotoxin testing.
PhRMA and BIO praise FDA efforts to use digital health technology in drug and biologic regulatory decisions.
Federal Register notice: FDA announces a 6/28 advisory committee meeting to discuss an Ipsen Biopharmaceuticals NDA for palovarotene capsules.
Phathom Pharmaceuticals resubmits its NDA for vonoprazan tablets to treat erosive gastroesophageal reflux disease, responding to a complete response l...
FDA approves a Celltrion BLA for Yuflyma (adalimumab-aaty), biosimilar copy of AbbVies blockbuster Humira.
Federal Register notice: FDA seeks comments on an information collection extension entitled Generic Clearance for the Collection of Qualitative Feedba...
FDA publishes a draft guidance on using generally accepted scientific knowledge in drug and biological product applications.
FDA extends by three weeks its review of a Sarepta Therapeutics BLA for SRP-9001 (delandistrogene moxeparvovec), a gene therapy product for treating a...